c
2
12
18
28
12
12
1a
14
e
12
16
a
a
2
2
a
20
32
1a
2a
19
Faculty
61 16
19
1
49
2
2
1a
32
34
1b
1d
18
38
5a
1d
2 29
1d
25
Scott Alan Peslak, MD, PhD
88
5a
Assistant Professor of Medicine (Hematology-Oncology)
7
5f
Department: Medicine
4
1
23
1f
Graduate Group Affiliations
8
a
b
1d
46
Contact information
81
4
3
3
1d
81
University of Pennsylvania, Department of Medicine, Division of Hematology/Oncology
35 Biomedical Research Building II/III, Room 809
31 421 Curie Blvd
Philadelphia, PA 19104
26
35 Biomedical Research Building II/III, Room 809
31 421 Curie Blvd
Philadelphia, PA 19104
35
a7
12
18
Publications
23 a
3
2
4
b
1f
23 a
13
Education:
21 8 BS 25 (Biochemistry, Philosophy) c
30 University of Scranton , 2006.
21 8 PhD 16 (Pathology) c
43 University of Rochester School of Medicine, 2012.
21 7 MD 16 (Medicine ) c
43 University of Rochester School of Medicine, 2014.
c
3
27
21 8 BS 25 (Biochemistry, Philosophy) c
30 University of Scranton , 2006.
21 8 PhD 16 (Pathology) c
43 University of Rochester School of Medicine, 2012.
21 7 MD 16 (Medicine ) c
43 University of Rochester School of Medicine, 2014.
c
Links
b6 Search PubMed for articles
d
5
3
3
92
Permanent linkb6 Search PubMed for articles
d
2 29
21
1e
1d
24
5e
71
e 29
27
Description of Clinical Expertise
149 I see patients in the UPenn Comprehensive Sickle Cell Program and Comprehensive Adult Thalassemia Program at the Perelman Center for Advanced Medicine as well as serve as the Director of the UPenn Comprehensive Adult Thalassemia Program and Gene Therapy Lead for patients with sickle cell disease and thalassemia.71
Description of Research Expertise
1ba Our lab is focused on improving therapeutic approaches for sickle cell disease (SCD) and beta-thalassemia via the study of key signaling pathways that regulate expression of the fetal form of hemoglobin. Our work spans the entire translational spectrum from basic science to pre-clinical studies, and we utilize a variety of genomic, pharmacologic, and functional approaches in both in vitro and in vivo red blood cell models.e 29
23
8d Castracani C.C., Bright M., Patel J., Peslak S.A., Cheng A., Breda L., Rivella S., Kwiatkowski J. e3 : Real-world comparative effects of curative and disease-modifying therapies on ineffective erythropoiesis in beta-thalassemia. American Society of Hematology Annual Meeting, Orlando, FL Dec 2025.
148 Cheng A.N., Gimotty P., Margolis D., Peslak S.A., Al-Samkari H, Roe A.H., Kwiatkowski J.L.: Development of a Prediction Model for Maternal Pregnancy Complications in Sickle Cell Disease. American Society of Hematology Annual Meeting, Orlando, FL Dec 2025.
16b Sheth S., Lal A., Appiah-Kubi A, Peslak S.A., Temin N.T., Coates T. : Real-world safety profile of twice-daily deferiprone for iron overload in patients with thalassemia syndromes. 20th Annual Sickle Cell and Thalassemia Conference (ASCAT), London, UK Oct 2025 Notes: "Poster Presentation"
169 Sheth S., Lal A., Appiah-Kubi A, Peslak S.A., Temin N.T., Coates T. : Real-world safety profile of twice-daily deferiprone for iron overload in patients with sickle cell disease. 20th Annual Sickle Cell and Thalassemia Conference (ASCAT), London, UK Oct 2025 Notes: "Poster Presentation"
153 Cheng A.N, Peslak S.A., Sheth S., Sayani S., Lal A.: High Morbidity in Adults with Non-Transfusion-Dependent Thalassemia Referred to U.S. Specialty Centers. 20th Annual Sickle Cell and Thalassemia Conference (ASCAT), London, UK Oct 2025 Notes: "Poster Presentation"
1a4 Al Ta’ani, O.; Mayrer, B.M.; Luche, N.M.; Siddique, S.M., Peslak, S.A.; Anderson, T.S.; Vajravelu, R.K.: Impact of Diagnostic Serum Ferritin Thresholds on Prevalence of Iron Deficiency Anemia: A Cross-Sectional Analysis of U.S. Adults. JAMA Internal Medicine Online Ahead of Print: e252311, Aug 2025 Notes: doi: 10.1001/jamainternmed.2025.2311.
168 Cheng A.N., Cohen J., Lundberg R.K., Sayani F.A., Chong E.A., Peslak S.A.: Progressive Anaemia and Splenomegaly in an Adult with HbE/Beta Thalassaemia. 1st TIF Pan American Conference on Thalassaemia and Other Haemoglobin Disorders, Washington, DC. Jul 2025 Notes: "Poster Presentation"
136 Huang, P., Peslak, S.A., Shehu, V., Keller, C.A., Giardine, B., Shi, J., Hardison, R.C., Blobel, G.A., Khandros, E.: Let-7 miRNAs repress HIC2 to regulate BCL11A transcription and hemoglobin switching. Blood 143(19): 1980-1991, May 2024.
1a9 Peslak S.A., Abbas T., Khandros E., Traxler E.A., Abdulmalik O., Giardine B.M., Keller C.A., Hardison R.C., Shi J., Blobel G.A. : Protein Phosphatase 6 Complex: Novel Regulator of Fetal Hemoglobin and Potential Therapeutic Target in Sickle Cell Disease. American Society of Hematology Annual Meeting, San Diego, CA Dec 2023 Notes: "Poster Presentation"
2c
7
1d
1f
Selected Publications
12b Cheng A.N., Peslak S.A., Sheth S., Sayani F., Lal A.: High morbidity in adults with non-transfusion-dependent thalassemia referred to U.S. specialty centers. American Society of Hematology Annual Meeting, Orlando, FL Dec 2025.8d Castracani C.C., Bright M., Patel J., Peslak S.A., Cheng A., Breda L., Rivella S., Kwiatkowski J. e3 : Real-world comparative effects of curative and disease-modifying therapies on ineffective erythropoiesis in beta-thalassemia. American Society of Hematology Annual Meeting, Orlando, FL Dec 2025.
148 Cheng A.N., Gimotty P., Margolis D., Peslak S.A., Al-Samkari H, Roe A.H., Kwiatkowski J.L.: Development of a Prediction Model for Maternal Pregnancy Complications in Sickle Cell Disease. American Society of Hematology Annual Meeting, Orlando, FL Dec 2025.
16b Sheth S., Lal A., Appiah-Kubi A, Peslak S.A., Temin N.T., Coates T. : Real-world safety profile of twice-daily deferiprone for iron overload in patients with thalassemia syndromes. 20th Annual Sickle Cell and Thalassemia Conference (ASCAT), London, UK Oct 2025 Notes: "Poster Presentation"
169 Sheth S., Lal A., Appiah-Kubi A, Peslak S.A., Temin N.T., Coates T. : Real-world safety profile of twice-daily deferiprone for iron overload in patients with sickle cell disease. 20th Annual Sickle Cell and Thalassemia Conference (ASCAT), London, UK Oct 2025 Notes: "Poster Presentation"
153 Cheng A.N, Peslak S.A., Sheth S., Sayani S., Lal A.: High Morbidity in Adults with Non-Transfusion-Dependent Thalassemia Referred to U.S. Specialty Centers. 20th Annual Sickle Cell and Thalassemia Conference (ASCAT), London, UK Oct 2025 Notes: "Poster Presentation"
1a4 Al Ta’ani, O.; Mayrer, B.M.; Luche, N.M.; Siddique, S.M., Peslak, S.A.; Anderson, T.S.; Vajravelu, R.K.: Impact of Diagnostic Serum Ferritin Thresholds on Prevalence of Iron Deficiency Anemia: A Cross-Sectional Analysis of U.S. Adults. JAMA Internal Medicine Online Ahead of Print: e252311, Aug 2025 Notes: doi: 10.1001/jamainternmed.2025.2311.
168 Cheng A.N., Cohen J., Lundberg R.K., Sayani F.A., Chong E.A., Peslak S.A.: Progressive Anaemia and Splenomegaly in an Adult with HbE/Beta Thalassaemia. 1st TIF Pan American Conference on Thalassaemia and Other Haemoglobin Disorders, Washington, DC. Jul 2025 Notes: "Poster Presentation"
136 Huang, P., Peslak, S.A., Shehu, V., Keller, C.A., Giardine, B., Shi, J., Hardison, R.C., Blobel, G.A., Khandros, E.: Let-7 miRNAs repress HIC2 to regulate BCL11A transcription and hemoglobin switching. Blood 143(19): 1980-1991, May 2024.
1a9 Peslak S.A., Abbas T., Khandros E., Traxler E.A., Abdulmalik O., Giardine B.M., Keller C.A., Hardison R.C., Shi J., Blobel G.A. : Protein Phosphatase 6 Complex: Novel Regulator of Fetal Hemoglobin and Potential Therapeutic Target in Sickle Cell Disease. American Society of Hematology Annual Meeting, San Diego, CA Dec 2023 Notes: "Poster Presentation"
2c
4d
22
22
7
10
a
a
2
2
19
18
10
22
10
11
c
5b © The Trustees of the University of Pennsylvania | Site best viewed a in a supported browser. | Site Design: 57 PMACS Web Team. 3 22
10